These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36357569)

  • 21. Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity.
    Setsu G; Goto M; Ito K; Taira T; Miyamoto M; Watanabe T; Higuchi S
    Biochem Biophys Res Commun; 2024 Jun; 715():149995. PubMed ID: 38685185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
    Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
    Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity.
    Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G
    ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
    Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
    Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
    Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS
    Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression.
    Huang J; Wang X; Li B; Shen S; Wang R; Tao H; Hu J; Yu J; Jiang H; Chen K; Luo C; Dang Y; Zhang Y
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35728870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of PD-1/PD-L1 checkpoint in arsenic lung tumorigenesis.
    Xu W; Cui J; Wu L; He C; Chen G
    Toxicol Appl Pharmacol; 2021 Sep; 426():115633. PubMed ID: 34166680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program.
    Arranz-Nicolás J; Martin-Salgado M; Adán-Barrientos I; Liébana R; Del Carmen Moreno-Ortíz M; Leitner J; Steinberger P; Ávila-Flores A; Merida I
    Cancer Immunol Immunother; 2021 Nov; 70(11):3277-3289. PubMed ID: 33837851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer Differentiation Inducer Chlorogenic Acid Suppresses PD-L1 Expression and Boosts Antitumor Immunity of PD-1 Antibody.
    Li R; Zhan Y; Ding X; Cui J; Han Y; Zhang J; Zhang J; Li W; Wang L; Jiang J
    Int J Biol Sci; 2024; 20(1):61-77. PubMed ID: 38164171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell-intrinsic PD-L1 ablation sustains effector CD8
    Wang X; Lu L; Hong X; Wu L; Yang C; Wang Y; Li W; Yang Y; Cao D; Di W; Deng L
    Cell Rep; 2024 Feb; 43(2):113712. PubMed ID: 38294903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
    Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
    Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.